Creabilis, a European biotechnology company specialising in the development of treatments for dermatology, inflammation and pain, has established a UK operation near Canterbury, Kent.
The site at Womenswold will handle the clinical development of the firm’s portfolio of new drugs.
The decision to move to Canterbury broadens Creabilis’ already strong links with Kent. The most recent additions to the firm’s senior management team, David Roblin, James Sandy, Alex Leech and Peter Spargo, all previously worked at Pfizer’s UK headquarters in Sandwich.
Creabilis is using recently raised funding of €15m to support the establishment of the new Kent site. The funds will also be used to further advance Creabilis’ pipeline including its lead product CT327, a treatment for psoriasis and atopic dermatitis currently in Phase II clinical trials.
Eliot Forster, chief executive of Creabilis, said: ‘Our decision to establish a presence in Kent is testimony to the quality of industry professionals we believe the region attracts as well as its exceptionally strong links with the international pharmaceutical industry.’